IBDEI2IE ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,42111,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,42112,0)
 ;;=E11.628^^192^2135^33
 ;;^UTILITY(U,$J,358.3,42112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42112,1,3,0)
 ;;=3^DM Type 2 w/ Skin Compl NEC
 ;;^UTILITY(U,$J,358.3,42112,1,4,0)
 ;;=4^E11.628
 ;;^UTILITY(U,$J,358.3,42112,2)
 ;;=^5002658
 ;;^UTILITY(U,$J,358.3,42113,0)
 ;;=E11.69^^192^2135^19
 ;;^UTILITY(U,$J,358.3,42113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42113,1,3,0)
 ;;=3^DM Type 2 w/ Complications NEC
 ;;^UTILITY(U,$J,358.3,42113,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,42113,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,42114,0)
 ;;=E11.8^^192^2135^20
 ;;^UTILITY(U,$J,358.3,42114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42114,1,3,0)
 ;;=3^DM Type 2 w/ Complications,Unspec
 ;;^UTILITY(U,$J,358.3,42114,1,4,0)
 ;;=4^E11.8
 ;;^UTILITY(U,$J,358.3,42114,2)
 ;;=^5002665
 ;;^UTILITY(U,$J,358.3,42115,0)
 ;;=E10.51^^192^2135^13
 ;;^UTILITY(U,$J,358.3,42115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42115,1,3,0)
 ;;=3^DM Type 1 w/ Diab Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,42115,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,42115,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,42116,0)
 ;;=E10.52^^192^2135^12
 ;;^UTILITY(U,$J,358.3,42116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42116,1,3,0)
 ;;=3^DM Type 1 w/ Diab Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,42116,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,42116,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,42117,0)
 ;;=E10.59^^192^2135^1
 ;;^UTILITY(U,$J,358.3,42117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42117,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Compl NEC
 ;;^UTILITY(U,$J,358.3,42117,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,42117,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,42118,0)
 ;;=E10.610^^192^2135^10
 ;;^UTILITY(U,$J,358.3,42118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42118,1,3,0)
 ;;=3^DM Type 1 w/ Diab Neuropathy Arthropathy
 ;;^UTILITY(U,$J,358.3,42118,1,4,0)
 ;;=4^E10.610
 ;;^UTILITY(U,$J,358.3,42118,2)
 ;;=^5002613
 ;;^UTILITY(U,$J,358.3,42119,0)
 ;;=E10.618^^192^2135^5
 ;;^UTILITY(U,$J,358.3,42119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42119,1,3,0)
 ;;=3^DM Type 1 w/ Diab Arthopathy NEC
 ;;^UTILITY(U,$J,358.3,42119,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,42119,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,42120,0)
 ;;=E10.620^^192^2135^7
 ;;^UTILITY(U,$J,358.3,42120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42120,1,3,0)
 ;;=3^DM Type 1 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,42120,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,42120,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,42121,0)
 ;;=E10.621^^192^2135^15
 ;;^UTILITY(U,$J,358.3,42121,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42121,1,3,0)
 ;;=3^DM Type 1 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,42121,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,42121,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,42122,0)
 ;;=E10.622^^192^2135^17
 ;;^UTILITY(U,$J,358.3,42122,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42122,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,42122,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,42122,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,42123,0)
 ;;=E10.628^^192^2135^16
 ;;^UTILITY(U,$J,358.3,42123,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42123,1,3,0)
 ;;=3^DM Type 1 w/ Skin Compl NEC
 ;;^UTILITY(U,$J,358.3,42123,1,4,0)
 ;;=4^E10.628
 ;;^UTILITY(U,$J,358.3,42123,2)
 ;;=^5002618
 ;;^UTILITY(U,$J,358.3,42124,0)
 ;;=E10.69^^192^2135^2
 ;;^UTILITY(U,$J,358.3,42124,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42124,1,3,0)
 ;;=3^DM Type 1 w/ Complications NEC
